Edap Tms (NASDAQ:EDAP) issued its earnings results on Wednesday. The medical equipment provider reported $0.01 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.01, Morningstar.com reports. Edap Tms had a positive return on equity of 2.51% and a negative net margin of 0.93%. The company had revenue of $11.50 million for the quarter, compared to analysts’ expectations of $13.25 million.
NASDAQ:EDAP traded down $0.88 during trading hours on Thursday, hitting $3.67. 2,934 shares of the company traded hands, compared to its average volume of 197,238. The company has a current ratio of 2.40, a quick ratio of 1.97 and a debt-to-equity ratio of 0.09. Edap Tms has a one year low of $1.35 and a one year high of $5.42. The stock has a market cap of $129.62 million, a PE ratio of 179.50 and a beta of 1.90.
A number of large investors have recently modified their holdings of EDAP. Naples Global Advisors LLC bought a new position in Edap Tms during the 4th quarter valued at $31,000. Commonwealth Equity Services LLC lifted its stake in Edap Tms by 27.0% during the 1st quarter. Commonwealth Equity Services LLC now owns 23,500 shares of the medical equipment provider’s stock valued at $70,000 after acquiring an additional 5,000 shares in the last quarter. Hilton Capital Management LLC bought a new position in Edap Tms during the 1st quarter valued at $75,000. Finally, Fosun International Ltd lifted its stake in Edap Tms by 46.0% during the 4th quarter. Fosun International Ltd now owns 249,143 shares of the medical equipment provider’s stock valued at $421,000 after acquiring an additional 78,516 shares in the last quarter. Institutional investors and hedge funds own 10.07% of the company’s stock.
A number of equities analysts recently issued reports on EDAP shares. HC Wainwright reiterated a “buy” rating and issued a $6.50 target price on shares of Edap Tms in a report on Wednesday, April 3rd. TheStreet upgraded Edap Tms from a “d+” rating to a “c-” rating in a research note on Thursday, February 14th. ValuEngine upgraded Edap Tms from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Finally, Zacks Investment Research cut Edap Tms from a “buy” rating to a “hold” rating in a research note on Wednesday, January 16th.
ILLEGAL ACTIVITY NOTICE: “Edap Tms (EDAP) Releases Earnings Results, Meets Estimates” was published by American Banking News and is owned by of American Banking News. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.americanbankingnews.com/2019/05/16/edap-tms-edap-releases-earnings-results-meets-estimates.html.
About Edap Tms
EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. The company operates in two divisions: High Intensity Focused Ultrasound (HIFU), and Urology Devices and Services (UDS).
Recommended Story: What is a back-end load?
Receive News & Ratings for Edap Tms Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms and related companies with MarketBeat.com's FREE daily email newsletter.